Similar articles

• Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.

  Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K. Serin IS, et al. Gynecol Endocrinol. 2008 Mar;24(3):117-21. doi: 10.1080/09513590801895559. Gynecol Endocrinol. 2008. PMID: 18335323
• No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial.

  McTiernan A, Sorensen B, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Rudolph RE, Stanczyk FZ, Schwartz RS, Potter JD. McTiernan A, et al. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1020-1. doi: 10.1158/1055-9965.EPI-04-0834. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15824183 Clinical Trial. No abstract available.
• Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.

  Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Lu L, et al. Cancer Invest. 2008 Mar;26(2):185-92. doi: 10.1080/07357900701638343. Cancer Invest. 2008. PMID: 18259951
• Clinical utility of insulin-like growth factor-I (IGF-I) and IGF binding protein-3 measurements in paediatric practice.

  Banerjee I, Clayton PE. Banerjee I, et al. Pediatr Endocrinol Rev. 2006 Jun;3(4):393-402. Pediatr Endocrinol Rev. 2006. PMID: 16816808 Review.
• Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.

  Renehan AG, Harvie M, Howell A. Renehan AG, et al. Endocr Relat Cancer. 2006 Jun;13(2):273-8. doi: 10.1677/erc.1.01219. Endocr Relat Cancer. 2006. PMID: 16728563 Review.